Melatonin and Solifenacin for Double-J Ureteral Stent Symptoms

Inclusion Criteria: 1. Age 18 to 60 years. 2. Patients undergoing unilateral ureteroscopy or ureteroscopic lithotripsy with insertion of a unilateral Double-J ureteral stent. 3. Ability to understand and complete the study questionnaires. 4. Willingness to participate and provide written informed consent. Exclusion Criteria: 1. Bilateral ureteral stents. 2. Stents inserted for malignant ureteral obstruction or non-stone reconstructive indications. 3. Known hypersensitivity or contraindication to solifenacin or melatonin. 4. History of acute or chronic urinary retention, or evidence of clinically significant bladder outlet obstruction at baseline. 5. History of narrow-angle glaucoma or other contraindications to antimuscarinic therapy, including gastric retention. 6. Significant hepatic impairment. 7. Severe renal impairment if judged clinically relevant to study medication safety. 8. Pre-existing moderate to severe lower urinary tract symptoms unrelated to the stent. 9. Recent use of antimuscarinics, alpha-blockers, or melatonin that may interfere with symptom assessment. 10. Pregnancy or lactation. 11. Inability to complete follow-up.